Clinical Cancer Research, Vol 2, Issue 6 1017-1030, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter

M Begemann, SA Kashimawo, YA Choi, S Kim, KM Christiansen, G Duigou, M Mueller, I Schieren, S Ghosh, D Fabbro, NM Lampen, DF Heitjan, PB Schiff, JN Bruce and IB Weinstein
Columbia-Presbyterian Cancer Center, Departments of Radiation Oncology, Neurological Surgery, Division of Biostatistics in the School of Public Health, Columbia-Presbyterian Medical Center, New York, USA.

Protein kinase C (PKC) plays a central role in signal transduction pathways that mediate the action of certain growth factors, tumor promoters, and cellular oncogenes. To explore whether PKC might be an appropriate target for the chemotherapy of human brain tumors, cell lines were established from five glioblastomas, one mixed gliosarcoma and glioblastoma, two astrocytomas, and one choroid plexus carcinoma. The staurosporine derivative CGP 41251, an inhibitor of PKC, inhibited cell proliferation in all nine cell lines with an IC50 in the range of 0.4 micrometer. Drug withdrawal and clonogenicity assays showed that CGP 41251 induced an irreversible growth arrest. Three cell lines were examined in detail: two human glioblastoma cell lines, GB-1 and GB-2, and one gliosarcoma cell line, GS-1. All of these three cell lines were highly aneuploid and displayed morphologies and immunohistochemical markers characteristic of the glial lineage. The compound 12-O-tetradecanoylphorbol-13-acetate (TPA), a tumor promoter and activator of PKC, also inhibited the growth of these cell lines. CGP 41251 in combination with TPA caused further growth inhibition. Cultures treated with CGP 41251 displayed an increase in the fraction of cells in G2-M, a decrease of cells in S phase, and no consistent effect on G0-G1. Immunohistochemical analyses demonstrated that growth inhibition by CGP 41251 was associated with the formation of giant nuclei with extensive fragmentation and apoptotic bodies. These effects of CGP 41251 were abrogated by withdrawal of serum from the medium or by exposure of these cells to aphidicolin, actinomycin D, cycloheximide, or TPA. In contrast to the effects seen with the glioblastoma cell lines, nontransformed astrocyte lines remained viable in the presence of 0.4 and 0.8 micrometer CGP 41251 and displayed only a slight increase in the fraction of giant nuclei with fragmentation. The antitumor activity of CGP 41251 was demonstrated in vivo against xenografts of the glioblastoma cell lines U87 MG and U373 MG. These findings suggest that CGP 41251 might be a useful agent for the treatment of glioblastomas.

This article has been cited by other articles:

				V. Martin, F. Herrera, P. Carrera-Gonzalez, G. Garcia-Santos, I. Antolin, J. Rodriguez-Blanco, and C. Rodriguez Intracellular Signaling Pathways Involved in the Cell Growth Inhibition of Glioma Cells by Melatonin Cancer Res., January 15, 2006; 66(2): 1081 - 1088. [Abstract] [Full Text] [PDF]

				J.-T. Yoon, A. F. Palazzo, D. Xiao, T. M. Delohery, P. E. Warburton, J. N. Bruce, W. J. Thompson, G. Sperl, C. Whitehead, J. Fetter, et al. CP248, a Derivative of Exisulind, Causes Growth Inhibition, Mitotic Arrest, and Abnormalities in Microtubule Polymerization in Glioma Cells Mol. Cancer Ther., April 1, 2002; 1(6): 393 - 404. [Abstract] [Full Text] [PDF]

				A. B. da Rocha, D.R.A. Mans, A. Regner, and G. Schwartsmann Targeting Protein Kinase C: New Therapeutic Opportunities Against High-Grade Malignant Gliomas? Oncologist, February 1, 2002; 7(1): 17 - 33. [Abstract] [Full Text] [PDF]

				H. A. Cocker, N. Tiffin, K. Pritchard-Jones, C. R. Pinkerton, and L. R. Kelland In Vitro Prevention of the Emergence of Multidrug Resistance in a Pediatric Rhabdomyosarcoma Cell Line Clin. Cancer Res., October 1, 2001; 7(10): 3193 - 3198. [Abstract] [Full Text] [PDF]

				A. Besson and V. W. Yong Involvement of p21Waf1/Cip1 in Protein Kinase C Alpha-Induced Cell Cycle Progression Mol. Cell. Biol., July 1, 2000; 20(13): 4580 - 4590. [Abstract] [Full Text]

				P. I. Meneses, L. E. Abrey, K. A. Hajjar, S. H. Gultekin, R. M. Duvoisin, K. I. Berns, and M. R. Rosenfeld Simplified Production of a Recombinant Human Angiostatin Derivative That Suppresses Intracerebral Glial Tumor Growth Clin. Cancer Res., November 1, 1999; 5(11): 3689 - 3694. [Abstract] [Full Text] [PDF]